Papers/PMID:24192015
Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.
Nutrition journal2013The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
coenzyme Q10 — decreases tumour necrosis factor alpha concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The subjects in the Q10-300 group had a significantly lower level of TNF-α than those in the placebo group at week 12 (P = 0.039).”
Quoted verbatim from Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 300 mg/day (150 mg twice daily) for 12 weeks
- Population
- Patients with coronary artery disease on statin therapy for at least one month; single-blind placebo-controlled trial, 42 completers (placebo n = 19, coenzyme Q10 n = 23); week 12 between-group comparison
Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.2013PMID:24192015Permalink